Unique ID issued by UMIN | UMIN000005815 |
---|---|
Receipt number | R000006875 |
Scientific Title | Efficacy of selective estrogen receptor modulator in pegylated interferon alpha plus ribavirin treatment for menopausal women with chronic hepatitis C women |
Date of disclosure of the study information | 2011/06/20 |
Last modified on | 2011/06/20 20:15:57 |
Efficacy of selective estrogen receptor modulator in pegylated interferon alpha plus ribavirin treatment for menopausal women with chronic hepatitis C women
Selective estrogen receptor modulator in pegylated interferon alpha plus ribavirin treatment
Efficacy of selective estrogen receptor modulator in pegylated interferon alpha plus ribavirin treatment for menopausal women with chronic hepatitis C women
Selective estrogen receptor modulator in pegylated interferon alpha plus ribavirin treatment
Japan |
Menopausal women with chronic hepatitis C
Hepato-biliary-pancreatic medicine |
Others
YES
In this study, we tested the hypothesis that selective estrogen receptor modulator (SERM), raloxifene, can give an impact of efficacy in pegylated interferon alpha plus ribavirin treatment as the current standard of care (SOC) for menopausal women with chronic hepatitis C women.
Others
Genotyping of the polymorphism in the interleukin-28B (IL28B) gene region (rs8099917) of chromosome 19 was performed on DNA collected from all patients.
Confirmatory
Pragmatic
Not applicable
Virological response was evaluated by Abbott RealTime PCR assay.
Interventional
Single arm
Randomized
Individual
Open -no one is blinded
Active
NO
NO
Institution is not considered as adjustment factor.
YES
Central registration
1
Treatment
Medicine |
Patients are randomly separated into two treatment groups: raloxifene plus pegylated interferon alpha plus ribavirin treatment as the current standard of care (SOC) and SOC only groups from 2010 to 2011.
50 | years-old | <= |
Not applicable |
Female
All patients are menopausal women with chronic hepatitis C and osteoporosis, and satisfy the following criteria: (1) positivity for hepatitis C virus (HCV) antibody and HCV RNA (2) a history of an increased alanine aminotransferase level for over six months.
Exclusion criteria for the study were: (1) positivity for antibody to human immunodeficiency virus or positivity for hepatitis B surface antigen; (2) clinical or biochemical evidence of hepatic decompensation; (3) excessive active alcohol consumption (> 60 g/day converted into ethanol) or drug abuse; (4) suspected hepatocellular carcinoma at entry; or (5) treatment with antiviral or immunosuppressive agents prior to enrollment.
120
1st name | |
Middle name | |
Last name | Jun Hayashi |
Kyushu University Hospital
Department of General Internal Medicine
3-1-1, Maidashi, Higashi-ku, Fukuoka, Japan
092-642-5909
1st name | |
Middle name | |
Last name | Norihiro Furusyo |
Kyushu University Hospital
Department of General Internal Medicine
3-1-1, Maidashi, Higashi-ku, Fukuoka, Japan
092-642-5909
Department of General Internal Medicine, Kyushu University Hospital
Department of General Internal Medicine, Kyushu University Hospital
NO
2011 | Year | 06 | Month | 20 | Day |
Unpublished
Completed
2008 | Year | 08 | Month | 15 | Day |
2008 | Year | 08 | Month | 01 | Day |
2011 | Year | 06 | Month | 01 | Day |
2011 | Year | 12 | Month | 01 | Day |
2011 | Year | 12 | Month | 01 | Day |
2011 | Year | 12 | Month | 01 | Day |
2011 | Year | 06 | Month | 20 | Day |
2011 | Year | 06 | Month | 20 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000006875
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |